ElectroCore Inc

ElectroCore CFO’s 3,000‑share sale is a routine, tax‑related move that won’t shift stock sentiment. Focus on leadership buying, clinical milestones, and market growth.

ElectroCore CFO’s 45k‑share purchase signals insider confidence in the company’s VNS neuro‑modulation platform, highlighting potential upside once FDA milestones and patent gains materialize.

Insider buying signals upside for ElectroCore: insider purchases, warrant acquisitions, and a leadership‑driven 30 % revenue target suggest potential gains amid regulatory and competitive gains.